GlycoVaxyn Winner of the Swiss Life Sciences Prize 2006

23.10.2006

The Swiss Life Sciences Prize 2006 was awarded to the company GlycoVaxyn AG. The prize of CHF 10'000, awarded for the third time, stands under the patronage of the Swiss Biotech Association and BioValley Basel, and is intended for young Swiss companies in the Pharma and Medtech sectors.

GlycoVaxyn, a spin-off company of the ETH Zürich, is developing novel conjugated vaccines. According to the company, over the last 20 years, such highly efficient vaccines have provided safe immunizations in humans. Their manufacturing involves a complex chemical conjugation step, which is circumvented by GlycoVaxyn's technology, where recombinant Escherichia coli bacteria link antigenic sugar chains, which originate from the cell surface of pathogenic bacteria, in vivo to carrier proteins. This biotechnological process will be developed to the point where novel conjugated vaccines offer dependable protection at an affordable prize.

Weitere News aus dem Ressort Wirtschaft & Finanzen

Meistgelesene News

Weitere News von unseren anderen Portalen

Unter die Lupe genommen: Die Welt der Mikroskopie